← 홈

전체 프로그램

ADC 1032 · Antibody 4683 · CGT 2713 · 다음 갱신 D-7 · 마지막 7월 21일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 545개
CGTBiologicstaleNanjing Legend Biotech Co.Phase 1

LUCAR-20SP cells (LUCAR-20SP cells)

Relapsed B-cell Non-Hodgkin Lymphoma; Refractory B-cell Non-Hodgkin Lymphoma · FRα

#FR#CGT#Phase1#세포유전치료#CAR-T+4
임상시험 1상태 RECRUITING
CGTBiologicstaleMedical College of WisconsinPhase 1

LV20.19 CAR T cells (LV20.19 CAR T cells)

Non Hodgkin Lymphoma; Diffuse Large B Cell Lymphoma · Non Hodgkin Lymphoma

#NonHodgkinLymphoma#CGT#Phase1#세포유전치료#CAR-T+3
임상시험 1상태 RECRUITING
AntibodystaleRochePhase 3

Lenalidomide and rituximab (R2, Lenalidomide and rituximab, Lenalidomide and rituximab (R2) in 28-day cycles for up to 12 cycles.)

Follicular Lymphoma (FL) · Follicular Lymphoma (FL)

#FollicularLymphomaFL#Antibody#Phase3#항체#면역항체+2
임상시험 1상태 RECRUITING
AntibodystaleGeorgetown UniversityPhase 1

Lenalidomide, Ibrutinib, Rituximab (Lenalidomide, Ibrutinib, Rituximab)

Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma · Chronic Lymphocytic Leukemia

#ChronicLymphocyticLeukemia#Antibody#Phase1#항체#면역항체+3
임상시험 1상태 DISCONTINUED
AntibodystaleADC TherapeuticsPhase 1

durvalumab (Imfinzi, Loncastuximab Tesirine and Durvalumab)

Diffuse Large B-Cell Lymphoma; Mantle Cell Lymphoma · Diffuse Large B-Cell Lymphoma

#DiffuseLargeB-CellLymphoma#Antibody#Phase1#항체#면역항체+3
효능 ORR 0%임상시험 1상태 DISCONTINUED
ADCBiologicstaleNew York Medical CollegePhase 2

MAD CPR 1 and 2 (MAD CPR 1 and 2)

Non-hodgkin Lymphoma; Hodgkin Lymphoma · Non-hodgkin Lymphoma

#Non-hodgkinLymphoma#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
임상시험 1상태 RECRUITING
CGTBiologicstaleMiltenyi Biomedicine GmbHPhase 2

MB-CART20.1 (MB-CART20.1)

Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma; Non-Hodgkin's Lymphoma · FRα

#FR#CGT#Phase2#세포유전치료#CAR-T+4
임상시험 1상태 ACTIVE
CGTBiologicstalePeking UniversityPhase 1

MC-19PD1 CAR-T cells (MC-19PD1 CAR-T cells)

Lymphoma · Lymphoma

#Lymphoma#CGT#Phase1#세포유전치료#CAR-T+2
임상시험 1상태 ACTIVE
CGTBiologicstaleTechnische Universität DresdenPhase 1

BCMA directed CAR T-cells (MDC-CAR-BCMA001, MDC-CAR-BCMA001 (BCMA directed CAR T-cells))

Neoplasms; Relapsed Diffuse Large B-cell Lymphoma (DLBCL) · BCMA

#BCMA#CGT#Phase1#세포유전치료#CAR-T+4
임상시험 1상태 RECRUITING
AntibodystaleMedImmune LLCPhase 2

durvalumab (Imfinzi, MEDI6469 Plus Durvalumab)

Advanced Solid Tumors; Aggressive B-cell Lymphomas · Advanced Solid Tumors

#AdvancedSolidTumors#Antibody#Phase2#항체#면역항체+3
효능 ORR 0%임상시험 1상태 DISCONTINUED
AntibodystaleMedImmune LLCPhase 2

MEDI6469 Plus Tremelimumab (MEDI6469 Plus Tremelimumab)

Advanced Solid Tumors; Aggressive B-cell Lymphomas · Advanced Solid Tumors

#AdvancedSolidTumors#Antibody#Phase2#항체#면역항체+3
효능 ORR 0%임상시험 1상태 DISCONTINUED
AntibodystaleMedImmune LLCPhase 2

MEDI6469 plus Rituximab (MEDI6469 plus Rituximab)

Advanced Solid Tumors; Aggressive B-cell Lymphomas · Advanced Solid Tumors

#AdvancedSolidTumors#Antibody#Phase2#항체#면역항체+3
효능 ORR 0%임상시험 1상태 DISCONTINUED
ADCBiologicstaleShanghai Miracogen Inc.Phase 1

MRG001 (MRG001)

Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (NHL) · FRα

#FR#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+2
임상시험 1상태 ACTIVE
AntibodystalePfizerPhase 1

PF-07901801 (Maplirpacept, Maplirpacept (PF-07901801))

Lymphoma; Multiple Myeloma · Lymphoma

#Lymphoma#Antibody#Phase1#항체#면역항체+3
임상시험 1상태 DISCONTINUED
ADCBiologicstaleMethylGene Inc.Phase 2

brentuximab vedotin (Adcetris, Mocetinostat Plus Brentuximab Vedotin)

Hodgkin Lymphoma · Hodgkin Lymphoma

#HodgkinLymphoma#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+1
효능 ORR 1%임상시험 1상태 ACTIVE
CGTBiologicstaleLiqun ZouPhase 1

Modified anti-CD19 CAR T cells (Modified anti-CD19 CAR T cells)

Refractory B-Cell Non-Hodgkin Lymphoma; Refractory Leukemia · CD19

#CD19#CGT#Phase1#세포유전치료#CAR-T+4
효능 ORR 25%임상시험 1상태 ACTIVE
CGTBiologicstaleHebei Senlang Biotechnology Inc…Phase 2

Nanobody-Based CD19/CD22 Tandem Dual CAR-T (Nanobody-Based CD19/CD22 Tandem Dual CAR-T)

Precursor B-Cell Lymphoblastic Leukemia-Lymphoma · CD19

#CD19#CGT#Phase2#세포유전치료#CAR-T+3
임상시험 1상태 RECRUITING
CGTBiologicstaleTimmune Biotech Inc.Phase 1

Novel CAR-T (Novel CAR-T)

B-cell Non Hodgkin Lymphoma; B-cell Acute Lymphoblastic Leukemia · B-cell Non Hodgkin Lymphoma

#B-cellNonHodgkinLymphoma#CGT#Phase1#세포유전치료#CAR-T+3
임상시험 1상태 ACTIVE
AntibodystaleNovartisPhase 3

OFATUMUMAB + DHAP (OFATUMUMAB + DHAP)

Lymphoma, Large-Cell, Diffuse · Lymphoma, Large-Cell, Diffuse

#LymphomaLarge-CellDiffuse#Antibody#Phase3#항체#면역항체+5
임상시험 1상태 ACTIVE
CGTBiologicstaleM.D. Anderson Cancer CenterPhase 2

ONC-PluReceptor NK cells (ONC-PluReceptor NK cells)

Recurrent B-Cell Non-Hodgkin Lymphoma; Refractory B-cell Non-Hodgkin Lymphoma · FRα

#FR#CGT#Phase2#세포유전치료#CAR-T+4
임상시험 1상태 RECRUITING

22 / 28 페이지

← 이전다음 →